MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer.-论文-万方医学网

作者： Zibing,Wang ^[1] ; Yuqing,Liu ^[2] ; Yong,Zhang ^[1] ; Yiman,Shang ^[1] ; Quanli,Gao ^[1]

作者单位： Department of Immunotherapy, Henan Cancer Hospital and Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China. ^[1] Department of Oncology, Third Affiliated Hospital of Xinxiang Medical College, Xinxiang 453003, China. ^[2]

主题词成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 肾细胞(Carcinoma, Renal Cell);队列研究(Cohort Studies);综合疗法(Combined Modality Therapy);细胞因子诱导杀伤细胞(Cytokine-Induced Killer Cells);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);免疫疗法(Immunotherapy);肾肿瘤(Kidney Neoplasms);男(雄)性(Male);中年人(Middle Aged);髓系细胞(Myeloid Cells);肿瘤分期(Neoplasm Staging);胰腺肿瘤(Pancreatic Neoplasms);预后(Prognosis);存活率(Survival Rate);青年人(Young Adult)

DOI 10.18632/oncotarget.6734

PMID 26716894

发布时间 2022-03-18

检索历史清除

MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer.

Oncotarget

相似文献

Oncotarget

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

MDSC-decreasing chemotherapy increases the efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma and pancreatic cancer.

Oncotarget

相似文献

Oncotarget

相关期刊

检索历史清除